The essential roles of m6A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma
Background Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m.sup.6A) modification of RNA has been suggested as a potential strategy to...
Saved in:
| Published in | Journal of experimental & clinical cancer research Vol. 41; no. 1; pp. 1 - 21 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central Ltd
25.01.2022
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m.sup.6A) modification of RNA has been suggested as a potential strategy to impede tumor progression. However, the roles of m.sup.6A modification in LUAD tumorigenesis is unknown. Methods Global m.sup.6A levels and expressions of m.sup.6A writers, erasers and readers were evaluated by RNA methylation assay, dot blot, immunoblotting, immunohistochemistry and ELISA in human LUAD, mouse models and cell lines. Cell viability, 3D-spheroid generation, in vivo LUAD formation, experiments in cell- and patient-derived xenograft mice and survival analysis were conducted to explore the impact of m.sup.6A on LUAD. The RNA-protein interactions, translation, putative m.sup.6A sites and glycolysis were explored in the investigation of the mechanism underlying how m.sup.6A stimulates tumorigenesis. Results The elevation of global m.sup.6A level in most human LUAD specimens resulted from the combined upregulation of m.sup.6A writer methyltransferase 3 (METTL3) and downregulation of eraser alkB homolog 5 (ALKBH5). Elevated global m.sup.6A level was associated with a poor overall survival in LUAD patients. Reducing m.sup.6A levels by knocking out METTL3 and overexpressing ALKBH5 suppressed 3D-spheroid generation in LUAD cells and intra-pulmonary tumor formation in mice. Mechanistically, m.sup.6A-dependent stimulation of glycolysis and tumorigenesis occurred via enolase 1 (ENO1). ENO1 mRNA was m.sup.6A methylated at 359 A, which facilitated it's binding with the m.sup.6A reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) and resulted in enhanced translation of ENO1. ENO1 positively correlated with METTL3 and global m.sup.6A levels, and negatively correlated with ALKBH5 in human LUAD. In addition, m.sup.6A-dependent elevation of ENO1 was associated with LUAD progression. In preclinical models, tumors with a higher global m.sup.6A level showed a more sensitive response to the inhibition of pan-methylation, glycolysis and ENO activity in LUAD. Conclusions The m.sup.6A-dependent stimulation of glycolysis and tumorigenesis in LUAD is at least partially orchestrated by the upregulation of METTL3, downregulation of ALKBH5, and stimulation of YTHDF1-mediated ENO1 translation. Blocking this mechanism may represent a potential treatment strategy for m.sup.6A-dependent LUAD. Keywords: METTL3, ALKBH5, YTHDF1, translation, lung cancer, RNA-protein interaction |
|---|---|
| AbstractList | Background Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m.sup.6A) modification of RNA has been suggested as a potential strategy to impede tumor progression. However, the roles of m.sup.6A modification in LUAD tumorigenesis is unknown. Methods Global m.sup.6A levels and expressions of m.sup.6A writers, erasers and readers were evaluated by RNA methylation assay, dot blot, immunoblotting, immunohistochemistry and ELISA in human LUAD, mouse models and cell lines. Cell viability, 3D-spheroid generation, in vivo LUAD formation, experiments in cell- and patient-derived xenograft mice and survival analysis were conducted to explore the impact of m.sup.6A on LUAD. The RNA-protein interactions, translation, putative m.sup.6A sites and glycolysis were explored in the investigation of the mechanism underlying how m.sup.6A stimulates tumorigenesis. Results The elevation of global m.sup.6A level in most human LUAD specimens resulted from the combined upregulation of m.sup.6A writer methyltransferase 3 (METTL3) and downregulation of eraser alkB homolog 5 (ALKBH5). Elevated global m.sup.6A level was associated with a poor overall survival in LUAD patients. Reducing m.sup.6A levels by knocking out METTL3 and overexpressing ALKBH5 suppressed 3D-spheroid generation in LUAD cells and intra-pulmonary tumor formation in mice. Mechanistically, m.sup.6A-dependent stimulation of glycolysis and tumorigenesis occurred via enolase 1 (ENO1). ENO1 mRNA was m.sup.6A methylated at 359 A, which facilitated it's binding with the m.sup.6A reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) and resulted in enhanced translation of ENO1. ENO1 positively correlated with METTL3 and global m.sup.6A levels, and negatively correlated with ALKBH5 in human LUAD. In addition, m.sup.6A-dependent elevation of ENO1 was associated with LUAD progression. In preclinical models, tumors with a higher global m.sup.6A level showed a more sensitive response to the inhibition of pan-methylation, glycolysis and ENO activity in LUAD. Conclusions The m.sup.6A-dependent stimulation of glycolysis and tumorigenesis in LUAD is at least partially orchestrated by the upregulation of METTL3, downregulation of ALKBH5, and stimulation of YTHDF1-mediated ENO1 translation. Blocking this mechanism may represent a potential treatment strategy for m.sup.6A-dependent LUAD. Keywords: METTL3, ALKBH5, YTHDF1, translation, lung cancer, RNA-protein interaction Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m6A) modification of RNA has been suggested as a potential strategy to impede tumor progression. However, the roles of m6A modification in LUAD tumorigenesis is unknown.BACKGROUNDLung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m6A) modification of RNA has been suggested as a potential strategy to impede tumor progression. However, the roles of m6A modification in LUAD tumorigenesis is unknown.Global m6A levels and expressions of m6A writers, erasers and readers were evaluated by RNA methylation assay, dot blot, immunoblotting, immunohistochemistry and ELISA in human LUAD, mouse models and cell lines. Cell viability, 3D-spheroid generation, in vivo LUAD formation, experiments in cell- and patient-derived xenograft mice and survival analysis were conducted to explore the impact of m6A on LUAD. The RNA-protein interactions, translation, putative m6A sites and glycolysis were explored in the investigation of the mechanism underlying how m6A stimulates tumorigenesis.METHODSGlobal m6A levels and expressions of m6A writers, erasers and readers were evaluated by RNA methylation assay, dot blot, immunoblotting, immunohistochemistry and ELISA in human LUAD, mouse models and cell lines. Cell viability, 3D-spheroid generation, in vivo LUAD formation, experiments in cell- and patient-derived xenograft mice and survival analysis were conducted to explore the impact of m6A on LUAD. The RNA-protein interactions, translation, putative m6A sites and glycolysis were explored in the investigation of the mechanism underlying how m6A stimulates tumorigenesis.The elevation of global m6A level in most human LUAD specimens resulted from the combined upregulation of m6A writer methyltransferase 3 (METTL3) and downregulation of eraser alkB homolog 5 (ALKBH5). Elevated global m6A level was associated with a poor overall survival in LUAD patients. Reducing m6A levels by knocking out METTL3 and overexpressing ALKBH5 suppressed 3D-spheroid generation in LUAD cells and intra-pulmonary tumor formation in mice. Mechanistically, m6A-dependent stimulation of glycolysis and tumorigenesis occurred via enolase 1 (ENO1). ENO1 mRNA was m6A methylated at 359 A, which facilitated it's binding with the m6A reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) and resulted in enhanced translation of ENO1. ENO1 positively correlated with METTL3 and global m6A levels, and negatively correlated with ALKBH5 in human LUAD. In addition, m6A-dependent elevation of ENO1 was associated with LUAD progression. In preclinical models, tumors with a higher global m6A level showed a more sensitive response to the inhibition of pan-methylation, glycolysis and ENO activity in LUAD.RESULTSThe elevation of global m6A level in most human LUAD specimens resulted from the combined upregulation of m6A writer methyltransferase 3 (METTL3) and downregulation of eraser alkB homolog 5 (ALKBH5). Elevated global m6A level was associated with a poor overall survival in LUAD patients. Reducing m6A levels by knocking out METTL3 and overexpressing ALKBH5 suppressed 3D-spheroid generation in LUAD cells and intra-pulmonary tumor formation in mice. Mechanistically, m6A-dependent stimulation of glycolysis and tumorigenesis occurred via enolase 1 (ENO1). ENO1 mRNA was m6A methylated at 359 A, which facilitated it's binding with the m6A reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) and resulted in enhanced translation of ENO1. ENO1 positively correlated with METTL3 and global m6A levels, and negatively correlated with ALKBH5 in human LUAD. In addition, m6A-dependent elevation of ENO1 was associated with LUAD progression. In preclinical models, tumors with a higher global m6A level showed a more sensitive response to the inhibition of pan-methylation, glycolysis and ENO activity in LUAD.The m6A-dependent stimulation of glycolysis and tumorigenesis in LUAD is at least partially orchestrated by the upregulation of METTL3, downregulation of ALKBH5, and stimulation of YTHDF1-mediated ENO1 translation. Blocking this mechanism may represent a potential treatment strategy for m6A-dependent LUAD.CONCLUSIONSThe m6A-dependent stimulation of glycolysis and tumorigenesis in LUAD is at least partially orchestrated by the upregulation of METTL3, downregulation of ALKBH5, and stimulation of YTHDF1-mediated ENO1 translation. Blocking this mechanism may represent a potential treatment strategy for m6A-dependent LUAD. Abstract Background Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m6A) modification of RNA has been suggested as a potential strategy to impede tumor progression. However, the roles of m6A modification in LUAD tumorigenesis is unknown. Methods Global m6A levels and expressions of m6A writers, erasers and readers were evaluated by RNA methylation assay, dot blot, immunoblotting, immunohistochemistry and ELISA in human LUAD, mouse models and cell lines. Cell viability, 3D-spheroid generation, in vivo LUAD formation, experiments in cell- and patient-derived xenograft mice and survival analysis were conducted to explore the impact of m6A on LUAD. The RNA-protein interactions, translation, putative m6A sites and glycolysis were explored in the investigation of the mechanism underlying how m6A stimulates tumorigenesis. Results The elevation of global m6A level in most human LUAD specimens resulted from the combined upregulation of m6A writer methyltransferase 3 (METTL3) and downregulation of eraser alkB homolog 5 (ALKBH5). Elevated global m6A level was associated with a poor overall survival in LUAD patients. Reducing m6A levels by knocking out METTL3 and overexpressing ALKBH5 suppressed 3D-spheroid generation in LUAD cells and intra-pulmonary tumor formation in mice. Mechanistically, m6A-dependent stimulation of glycolysis and tumorigenesis occurred via enolase 1 (ENO1). ENO1 mRNA was m6A methylated at 359 A, which facilitated it’s binding with the m6A reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) and resulted in enhanced translation of ENO1. ENO1 positively correlated with METTL3 and global m6A levels, and negatively correlated with ALKBH5 in human LUAD. In addition, m6A-dependent elevation of ENO1 was associated with LUAD progression. In preclinical models, tumors with a higher global m6A level showed a more sensitive response to the inhibition of pan-methylation, glycolysis and ENO activity in LUAD. Conclusions The m6A-dependent stimulation of glycolysis and tumorigenesis in LUAD is at least partially orchestrated by the upregulation of METTL3, downregulation of ALKBH5, and stimulation of YTHDF1-mediated ENO1 translation. Blocking this mechanism may represent a potential treatment strategy for m6A-dependent LUAD. Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m.sup.6A) modification of RNA has been suggested as a potential strategy to impede tumor progression. However, the roles of m.sup.6A modification in LUAD tumorigenesis is unknown. Global m.sup.6A levels and expressions of m.sup.6A writers, erasers and readers were evaluated by RNA methylation assay, dot blot, immunoblotting, immunohistochemistry and ELISA in human LUAD, mouse models and cell lines. Cell viability, 3D-spheroid generation, in vivo LUAD formation, experiments in cell- and patient-derived xenograft mice and survival analysis were conducted to explore the impact of m.sup.6A on LUAD. The RNA-protein interactions, translation, putative m.sup.6A sites and glycolysis were explored in the investigation of the mechanism underlying how m.sup.6A stimulates tumorigenesis. The elevation of global m.sup.6A level in most human LUAD specimens resulted from the combined upregulation of m.sup.6A writer methyltransferase 3 (METTL3) and downregulation of eraser alkB homolog 5 (ALKBH5). Elevated global m.sup.6A level was associated with a poor overall survival in LUAD patients. Reducing m.sup.6A levels by knocking out METTL3 and overexpressing ALKBH5 suppressed 3D-spheroid generation in LUAD cells and intra-pulmonary tumor formation in mice. Mechanistically, m.sup.6A-dependent stimulation of glycolysis and tumorigenesis occurred via enolase 1 (ENO1). ENO1 mRNA was m.sup.6A methylated at 359 A, which facilitated it's binding with the m.sup.6A reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) and resulted in enhanced translation of ENO1. ENO1 positively correlated with METTL3 and global m.sup.6A levels, and negatively correlated with ALKBH5 in human LUAD. In addition, m.sup.6A-dependent elevation of ENO1 was associated with LUAD progression. In preclinical models, tumors with a higher global m.sup.6A level showed a more sensitive response to the inhibition of pan-methylation, glycolysis and ENO activity in LUAD. The m.sup.6A-dependent stimulation of glycolysis and tumorigenesis in LUAD is at least partially orchestrated by the upregulation of METTL3, downregulation of ALKBH5, and stimulation of YTHDF1-mediated ENO1 translation. Blocking this mechanism may represent a potential treatment strategy for m.sup.6A-dependent LUAD. Background Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from satisfactory. Recently, targeting N6-methyladenosine (m6A) modification of RNA has been suggested as a potential strategy to impede tumor progression. However, the roles of m6A modification in LUAD tumorigenesis is unknown. Methods Global m6A levels and expressions of m6A writers, erasers and readers were evaluated by RNA methylation assay, dot blot, immunoblotting, immunohistochemistry and ELISA in human LUAD, mouse models and cell lines. Cell viability, 3D-spheroid generation, in vivo LUAD formation, experiments in cell- and patient-derived xenograft mice and survival analysis were conducted to explore the impact of m6A on LUAD. The RNA-protein interactions, translation, putative m6A sites and glycolysis were explored in the investigation of the mechanism underlying how m6A stimulates tumorigenesis. Results The elevation of global m6A level in most human LUAD specimens resulted from the combined upregulation of m6A writer methyltransferase 3 (METTL3) and downregulation of eraser alkB homolog 5 (ALKBH5). Elevated global m6A level was associated with a poor overall survival in LUAD patients. Reducing m6A levels by knocking out METTL3 and overexpressing ALKBH5 suppressed 3D-spheroid generation in LUAD cells and intra-pulmonary tumor formation in mice. Mechanistically, m6A-dependent stimulation of glycolysis and tumorigenesis occurred via enolase 1 (ENO1). ENO1 mRNA was m6A methylated at 359 A, which facilitated it’s binding with the m6A reader YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) and resulted in enhanced translation of ENO1. ENO1 positively correlated with METTL3 and global m6A levels, and negatively correlated with ALKBH5 in human LUAD. In addition, m6A-dependent elevation of ENO1 was associated with LUAD progression. In preclinical models, tumors with a higher global m6A level showed a more sensitive response to the inhibition of pan-methylation, glycolysis and ENO activity in LUAD. Conclusions The m6A-dependent stimulation of glycolysis and tumorigenesis in LUAD is at least partially orchestrated by the upregulation of METTL3, downregulation of ALKBH5, and stimulation of YTHDF1-mediated ENO1 translation. Blocking this mechanism may represent a potential treatment strategy for m6A-dependent LUAD. |
| ArticleNumber | 36 |
| Audience | Academic |
| Author | Xue, Xiangfei Miao, Yayou Wang, Jiayi Xu, Xin Guo, Wanxin Li, You Cui, Jiangtao Guo, Susu Wang, Yikun Zhang, Xiao Tian, Xiaoting Liu, Xiaoxin Meng, Fanyu Xia, Jinjing Qiu, Shiyu Yu, Keke Yu, Yongchun Ma, Lifang |
| Author_xml | – sequence: 1 givenname: Lifang surname: Ma fullname: Ma, Lifang – sequence: 2 givenname: Xiangfei surname: Xue fullname: Xue, Xiangfei – sequence: 3 givenname: Xiao surname: Zhang fullname: Zhang, Xiao – sequence: 4 givenname: Keke surname: Yu fullname: Yu, Keke – sequence: 5 givenname: Xin surname: Xu fullname: Xu, Xin – sequence: 6 givenname: Xiaoting surname: Tian fullname: Tian, Xiaoting – sequence: 7 givenname: Yayou surname: Miao fullname: Miao, Yayou – sequence: 8 givenname: Fanyu surname: Meng fullname: Meng, Fanyu – sequence: 9 givenname: Xiaoxin surname: Liu fullname: Liu, Xiaoxin – sequence: 10 givenname: Susu surname: Guo fullname: Guo, Susu – sequence: 11 givenname: Shiyu surname: Qiu fullname: Qiu, Shiyu – sequence: 12 givenname: Yikun surname: Wang fullname: Wang, Yikun – sequence: 13 givenname: Jiangtao surname: Cui fullname: Cui, Jiangtao – sequence: 14 givenname: Wanxin surname: Guo fullname: Guo, Wanxin – sequence: 15 givenname: You surname: Li fullname: Li, You – sequence: 16 givenname: Jinjing surname: Xia fullname: Xia, Jinjing – sequence: 17 givenname: Yongchun surname: Yu fullname: Yu, Yongchun – sequence: 18 givenname: Jiayi orcidid: 0000-0003-1688-2864 surname: Wang fullname: Wang, Jiayi |
| BookMark | eNp9Ul1rFDEUHaRiP_QP-BQQxJepSWby9SIspa2F0oLU55DmYzZLJlmTGWHxz5vdLdotIiHccO855-Ym57Q5iinapnmP4DlCnH4uqIM9bSFGdWMIW_KqOUGM0FYISo-enY-b01JWEFIkkHjTHHcEMk4gOWl-PSwtsKXYOHkVQE7BFpAcGOkCfLtbgDEZ77xWk08RTAmUyY9zUJMFl3f3qDV2baOpZDCEjU5hU3wBKhowzWPKfrDRbjM-gjDHAagKTVpl7WMa1dvmtVOh2HdP8az5fnX5cPG1vb2_vrlY3LaaQDS1CNUonLKYEkYhwoJzrqmj1GHRcdVDox1zthYJxYZjpCnlqH80WHHMXHfW3Ox1TVIruc5-VHkjk_Jyl0h5kCpPXgcrK1sbrGFXxXvktGCih12nKIPMkY5VrS97rfX8OFqj6-hZhQPRw0r0Szmkn5IzziETVeDTk0BOP2ZbJjn6om0IKto0F4kpxoIwzmCFfngBXaU5x_pUFVW_nnWI4L-oQdUBfHSp9tVbUbmgoiOoZ7u25_9A1WXs6HX1lfM1f0D4-IywtCpMy5LCvDVCOQTiPVDnVEq27s9jICi3PpV7n8rqU7nzqSSVxF-QtJ92JqvX8uF_1N_DLurE |
| CitedBy_id | crossref_primary_10_1038_s41416_023_02246_6 crossref_primary_10_1016_j_mtbio_2022_100503 crossref_primary_10_1016_j_ymthe_2022_12_013 crossref_primary_10_1038_s41420_024_02092_2 crossref_primary_10_1186_s12964_023_01360_5 crossref_primary_10_1038_s41417_023_00661_8 crossref_primary_10_1016_j_cellin_2022_100075 crossref_primary_10_1002_ctm2_70192 crossref_primary_10_1016_j_bcp_2024_116220 crossref_primary_10_1002_1878_0261_13326 crossref_primary_10_1186_s11658_022_00404_x crossref_primary_10_18632_aging_204371 crossref_primary_10_1186_s13046_024_03181_x crossref_primary_10_1016_j_gene_2023_147975 crossref_primary_10_1038_s41598_023_51108_x crossref_primary_10_2174_1566523222666220830150446 crossref_primary_10_1186_s43556_024_00229_4 crossref_primary_10_1002_ddr_70004 crossref_primary_10_1016_j_yexcr_2023_113778 crossref_primary_10_3389_fgene_2022_993322 crossref_primary_10_3390_molecules29010140 crossref_primary_10_1002_mc_23826 crossref_primary_10_1186_s13045_023_01477_7 crossref_primary_10_1186_s40364_023_00483_8 crossref_primary_10_1002_wrna_1829 crossref_primary_10_1002_tox_24272 crossref_primary_10_1038_s42003_024_06755_9 crossref_primary_10_1016_j_ecoenv_2023_115288 crossref_primary_10_3389_fimmu_2024_1464042 crossref_primary_10_1007_s13402_023_00864_z crossref_primary_10_3390_genes13122381 crossref_primary_10_1038_s41571_023_00774_x crossref_primary_10_1016_j_aca_2023_341796 crossref_primary_10_1038_s41420_024_02133_w crossref_primary_10_1186_s12935_024_03528_6 crossref_primary_10_1016_j_bbrc_2024_150011 crossref_primary_10_1093_narcan_zcae009 crossref_primary_10_1186_s40001_025_02407_8 crossref_primary_10_3390_biom13020243 crossref_primary_10_1016_j_canlet_2024_217002 crossref_primary_10_1186_s12943_022_01704_8 crossref_primary_10_1038_s41401_024_01264_1 crossref_primary_10_1021_acs_analchem_4c01610 crossref_primary_10_1186_s12964_023_01401_z crossref_primary_10_1186_s12943_023_01841_8 crossref_primary_10_1002_jcla_24636 crossref_primary_10_1021_acsnano_3c03050 crossref_primary_10_1186_s13578_024_01194_9 crossref_primary_10_1002_mco2_70042 crossref_primary_10_1038_s41392_024_01777_5 crossref_primary_10_1016_j_ijbiomac_2023_127769 crossref_primary_10_1016_j_lfs_2024_123146 crossref_primary_10_1186_s12967_024_05847_8 crossref_primary_10_1038_s41388_024_02992_8 crossref_primary_10_3724_abbs_2024109 crossref_primary_10_1016_j_biopha_2024_116479 crossref_primary_10_2174_0929867331666230901110629 crossref_primary_10_3389_fimmu_2023_1162607 crossref_primary_10_3389_fimmu_2023_1231898 crossref_primary_10_1002_ctm2_1784 crossref_primary_10_1111_cas_16394 crossref_primary_10_1186_s11658_024_00622_5 |
| Cites_doi | 10.1016/j.molcel.2019.04.025 10.1016/j.tranon.2020.100910 10.1158/0008-5472.CAN-05-0453 10.1186/s12935-020-01679-w 10.3389/fonc.2020.01561 10.1186/1476-4598-13-14 10.1053/j.gastro.2012.03.037 10.1007/s11684-018-0654-8 10.1073/pnas.71.10.3971 10.3389/fphar.2020.572627 10.1186/s13059-018-1435-z 10.1111/jcmm.15997 10.1186/s12943-020-01204-7 10.1186/s12943-019-1088-x 10.1016/j.ccell.2018.01.010 10.1038/s41467-019-12801-6 10.1016/S0014-5793(00)01494-0 10.1016/j.tig.2019.10.011 10.1038/nchembio.2195 10.3390/ijms22115518 10.1038/s41467-018-06376-x 10.1038/nature22334 10.1158/0008-5472.CAN-20-3543 10.1016/j.molcel.2020.06.003 10.1371/journal.pone.0012961 10.1186/s13045-015-0117-5 10.1186/s13045-021-01123-0 10.1038/s41419-021-03739-z 10.1186/s12943-019-1109-9 10.1186/s13045-020-00872-8 10.1016/j.cell.2018.12.040 10.1186/s12943-020-01249-8 10.1016/j.omtn.2020.12.001 10.1111/cas.13998 10.1186/s12943-020-01190-w 10.1038/s41422-018-0034-6 10.1038/s41588-020-0644-z 10.1136/gutjnl-2019-319639 10.1016/j.tibs.2015.12.001 10.1093/nar/gkz157 10.1186/s12943-019-1099-7 10.1111/jcmm.14763 10.1039/D0SC03628E 10.1074/jbc.M111.267294 10.1038/ncomms15737 10.1016/j.freeradbiomed.2021.03.023 10.4110/in.2015.15.6.291 10.1074/jbc.274.27.18981 10.1186/s13287-021-02160-9 10.1038/s41419-021-03763-z 10.3892/or.2021.8114 10.1038/s41556-020-00580-y 10.1016/j.ccr.2012.02.014 10.3322/caac.21660 10.1038/s41419-019-2127-7 10.1016/j.molcel.2016.03.021 10.1016/j.csbj.2021.07.014 10.1158/2159-8290.CD-20-0331 10.1038/s41419-018-0376-5 10.1016/j.redox.2020.101801 10.3389/fcell.2019.00061 10.1186/s12943-020-01161-1 10.7150/thno.40860 10.1038/s41586-018-0666-1 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). The Author(s) 2022 |
| Copyright_xml | – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). – notice: The Author(s) 2022 |
| DBID | AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13046-021-02200-5 |
| DatabaseName | CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-9966 |
| EndPage | 21 |
| ExternalDocumentID | oai_doaj_org_article_d82cd2c0366f41fc9794033a6707f537 PMC8788079 A693514779 10_1186_s13046_021_02200_5 |
| GeographicLocations | China United States--US |
| GeographicLocations_xml | – name: China – name: United States--US |
| GrantInformation_xml | – fundername: ; grantid: Project of Clinical Research Supporting System, Clinical Medicine First-class Discipline – fundername: ; grantid: Talent training plan of shanghai chest hospital in 2020 – fundername: ; grantid: 19YF1444800 – fundername: ; grantid: 21140902800 – fundername: ; grantid: 2021YNZYJ01, 2021YNZYY02, 2021YNZYY01 – fundername: ; grantid: 81871907, 81822029, 82173015, 82102792, 81872288, 81902315, 81902869, 81774291 – fundername: ; grantid: 20191834 |
| GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c501t-11c509fae265760129888c6f66f2938a40dcf7fe576562d821c66814bd2a827f3 |
| IEDL.DBID | M48 |
| ISSN | 1756-9966 0392-9078 |
| IngestDate | Wed Aug 27 01:31:38 EDT 2025 Thu Aug 21 13:51:22 EDT 2025 Fri Jul 11 15:20:03 EDT 2025 Fri Jul 25 03:38:14 EDT 2025 Tue Jun 17 21:28:31 EDT 2025 Tue Jun 10 20:29:35 EDT 2025 Thu May 22 21:23:29 EDT 2025 Thu Apr 24 23:11:32 EDT 2025 Tue Jul 01 02:26:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c501t-11c509fae265760129888c6f66f2938a40dcf7fe576562d821c66814bd2a827f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-1688-2864 |
| OpenAccessLink | https://www.proquest.com/docview/2630473152?pq-origsite=%requestingapplication% |
| PMID | 35078505 |
| PQID | 2630473152 |
| PQPubID | 105475 |
| PageCount | 21 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d82cd2c0366f41fc9794033a6707f537 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8788079 proquest_miscellaneous_2622957870 proquest_journals_2630473152 gale_infotracmisc_A693514779 gale_infotracacademiconefile_A693514779 gale_healthsolutions_A693514779 crossref_primary_10_1186_s13046_021_02200_5 crossref_citationtrail_10_1186_s13046_021_02200_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-25 |
| PublicationDateYYYYMMDD | 2022-01-25 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Journal of experimental & clinical cancer research |
| PublicationYear | 2022 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | T Wang (2200_CR9) 2020; 19 M Zhuang (2200_CR62) 2019; 47 R Jia (2200_CR22) 2019; 18 Y Shen (2200_CR43) 2021; 25 ES Birkeland (2200_CR17) 2020; 10 D Chiluiza (2200_CR39) 2011; 286 Q Wang (2200_CR21) 2020; 69 RT Mertens (2200_CR20) 2020; 11 BB Hu (2200_CR37) 2019; 18 S Feo (2200_CR50) 2000; 473 L Wang (2200_CR19) 2019; 11 2200_CR47 J Choi (2200_CR30) 2015; 15 Y Li (2200_CR45) 2021; 12 Y Zhao (2200_CR12) 2020; 13 L He (2200_CR7) 2019; 18 H Huang (2200_CR8) 2020; 22 D Dixit (2200_CR35) 2021; 11 Z Zhu (2200_CR65) 2005; 65 2200_CR54 J Dai (2200_CR31) 2018; 9 S Chen (2200_CR51) 2018; 9 C Shen (2200_CR14) 2020; 19 S Xie (2200_CR15) 2020; 20 2200_CR18 H Shi (2200_CR61) 2018; 563 H Shi (2200_CR6) 2019; 74 B Czogalla (2200_CR29) 2021; 14 C Ma (2200_CR11) 2018; 19 C Cheng (2200_CR42) 2021; 23 L Ma (2200_CR23) 2021; 168 X Yang (2200_CR59) 2021; 12 R Desrosiers (2200_CR40) 1974; 71 D Jin (2200_CR44) 2020; 19 J Tong (2200_CR13) 2018; 12 PG Leonard (2200_CR32) 2016; 12 X Shu (2200_CR55) 2021; 12 X Deng (2200_CR10) 2018; 28 L Li (2200_CR58) 2018; 33 H Sung (2200_CR1) 2021; 71 X Qian (2200_CR41) 2021; 14 R Chen (2200_CR56) 2020; 24 S Lin (2200_CR46) 2016; 62 H Huang (2200_CR4) 2020; 36 L Ma (2200_CR24) 2021; 38 M Lo Presti (2200_CR49) 2010; 5 SY Jeong (2200_CR64) 1999; 274 QF Fu (2200_CR53) 2015; 8 M Wang (2200_CR5) 2020; 19 Z Zhang (2200_CR34) 2020; 52 Y Lin (2200_CR38) 2020; 79 B Gyorffy (2200_CR27) 2021; 19 L Kan (2200_CR36) 2017; 8 C Jin (2200_CR26) 2019; 176 T Hu (2200_CR52) 2020; 10 M Didiasova (2200_CR28) 2019; 7 MV Liberti (2200_CR57) 2016; 41 L Wang (2200_CR2) 2019; 110 R Li (2200_CR3) 2020; 11 NA Manieri (2200_CR60) 2012; 143 Y Shi (2200_CR63) 2019; 10 RA Vaughan (2200_CR33) 2014; 13 PS Ward (2200_CR16) 2012; 21 T Tammela (2200_CR25) 2017; 545 J Zhou (2200_CR48) 2019; 10 |
| References_xml | – volume: 74 start-page: 640 year: 2019 ident: 2200_CR6 publication-title: Mol Cell doi: 10.1016/j.molcel.2019.04.025 – volume: 14 start-page: 100910 year: 2021 ident: 2200_CR29 publication-title: Transl Oncol doi: 10.1016/j.tranon.2020.100910 – volume: 65 start-page: 7023 year: 2005 ident: 2200_CR65 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-0453 – volume: 20 start-page: 585 year: 2020 ident: 2200_CR15 publication-title: Cancer Cell Int doi: 10.1186/s12935-020-01679-w – volume: 10 start-page: 1561 year: 2020 ident: 2200_CR17 publication-title: Front Oncol doi: 10.3389/fonc.2020.01561 – volume: 13 start-page: 14 year: 2014 ident: 2200_CR33 publication-title: Mol Cancer doi: 10.1186/1476-4598-13-14 – volume: 143 start-page: 110-21 e10 year: 2012 ident: 2200_CR60 publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.03.037 – volume: 12 start-page: 481 year: 2018 ident: 2200_CR13 publication-title: Front Med doi: 10.1007/s11684-018-0654-8 – volume: 71 start-page: 3971 year: 1974 ident: 2200_CR40 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.71.10.3971 – volume: 11 start-page: 572627 year: 2020 ident: 2200_CR3 publication-title: Front Pharmacol doi: 10.3389/fphar.2020.572627 – volume: 19 start-page: 68 year: 2018 ident: 2200_CR11 publication-title: Genome Biol doi: 10.1186/s13059-018-1435-z – volume: 25 start-page: 284 year: 2021 ident: 2200_CR43 publication-title: J Cell Mol Med doi: 10.1111/jcmm.15997 – volume: 19 start-page: 88 year: 2020 ident: 2200_CR9 publication-title: Mol Cancer doi: 10.1186/s12943-020-01204-7 – volume: 18 start-page: 161 year: 2019 ident: 2200_CR22 publication-title: Mol Cancer doi: 10.1186/s12943-019-1088-x – volume: 33 start-page: 368-85 e7 year: 2018 ident: 2200_CR58 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.01.010 – volume: 10 start-page: 4892 year: 2019 ident: 2200_CR63 publication-title: Nat Commun doi: 10.1038/s41467-019-12801-6 – volume: 11 start-page: 4470 year: 2019 ident: 2200_CR19 publication-title: Am J Transl Res – volume: 473 start-page: 47 year: 2000 ident: 2200_CR50 publication-title: FEBS Lett doi: 10.1016/S0014-5793(00)01494-0 – volume: 36 start-page: 44 year: 2020 ident: 2200_CR4 publication-title: Trends Genet doi: 10.1016/j.tig.2019.10.011 – volume: 12 start-page: 1053 year: 2016 ident: 2200_CR32 publication-title: Nat Chem Biol doi: 10.1038/nchembio.2195 – ident: 2200_CR18 doi: 10.3390/ijms22115518 – volume: 9 start-page: 3850 year: 2018 ident: 2200_CR31 publication-title: Nat Commun doi: 10.1038/s41467-018-06376-x – volume: 545 start-page: 355 year: 2017 ident: 2200_CR25 publication-title: Nature doi: 10.1038/nature22334 – ident: 2200_CR54 doi: 10.1158/0008-5472.CAN-20-3543 – volume: 79 start-page: 575-87 e7 year: 2020 ident: 2200_CR38 publication-title: Mol Cell doi: 10.1016/j.molcel.2020.06.003 – volume: 5 start-page: e12961 year: 2010 ident: 2200_CR49 publication-title: PLoS One doi: 10.1371/journal.pone.0012961 – volume: 8 start-page: 22 year: 2015 ident: 2200_CR53 publication-title: J Hematol Oncol doi: 10.1186/s13045-015-0117-5 – volume: 14 start-page: 112 year: 2021 ident: 2200_CR41 publication-title: J Hematol Oncol doi: 10.1186/s13045-021-01123-0 – volume: 12 start-page: 462 year: 2021 ident: 2200_CR59 publication-title: Cell Death Dis doi: 10.1038/s41419-021-03739-z – volume: 18 start-page: 176 year: 2019 ident: 2200_CR7 publication-title: Mol Cancer doi: 10.1186/s12943-019-1109-9 – volume: 13 start-page: 35 year: 2020 ident: 2200_CR12 publication-title: J Hematol Oncol doi: 10.1186/s13045-020-00872-8 – volume: 176 start-page: 998-1013 e16 year: 2019 ident: 2200_CR26 publication-title: Cell doi: 10.1016/j.cell.2018.12.040 – volume: 19 start-page: 130 year: 2020 ident: 2200_CR5 publication-title: Mol Cancer doi: 10.1186/s12943-020-01249-8 – volume: 23 start-page: 487 year: 2021 ident: 2200_CR42 publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2020.12.001 – volume: 110 start-page: 1609 year: 2019 ident: 2200_CR2 publication-title: Cancer Sci doi: 10.1111/cas.13998 – volume: 19 start-page: 72 year: 2020 ident: 2200_CR14 publication-title: Mol Cancer doi: 10.1186/s12943-020-01190-w – volume: 28 start-page: 507 year: 2018 ident: 2200_CR10 publication-title: Cell Res doi: 10.1038/s41422-018-0034-6 – volume: 52 start-page: 939 year: 2020 ident: 2200_CR34 publication-title: Nat Genet doi: 10.1038/s41588-020-0644-z – volume: 69 start-page: 1193 year: 2020 ident: 2200_CR21 publication-title: Gut doi: 10.1136/gutjnl-2019-319639 – volume: 41 start-page: 211 year: 2016 ident: 2200_CR57 publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2015.12.001 – volume: 47 start-page: 4765 year: 2019 ident: 2200_CR62 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkz157 – volume: 18 start-page: 178 year: 2019 ident: 2200_CR37 publication-title: Mol Cancer doi: 10.1186/s12943-019-1099-7 – volume: 24 start-page: 2123 year: 2020 ident: 2200_CR56 publication-title: J Cell Mol Med doi: 10.1111/jcmm.14763 – volume: 11 start-page: 10465 year: 2020 ident: 2200_CR20 publication-title: Chem Sci doi: 10.1039/D0SC03628E – volume: 286 start-page: 31288 year: 2011 ident: 2200_CR39 publication-title: J Biol Chem doi: 10.1074/jbc.M111.267294 – volume: 8 start-page: 15737 year: 2017 ident: 2200_CR36 publication-title: Nat Commun doi: 10.1038/ncomms15737 – volume: 168 start-page: 25 year: 2021 ident: 2200_CR23 publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2021.03.023 – volume: 15 start-page: 291 year: 2015 ident: 2200_CR30 publication-title: Immune Netw doi: 10.4110/in.2015.15.6.291 – volume: 274 start-page: 18981 year: 1999 ident: 2200_CR64 publication-title: J Biol Chem doi: 10.1074/jbc.274.27.18981 – volume: 12 start-page: 119 year: 2021 ident: 2200_CR55 publication-title: Stem Cell Res Ther doi: 10.1186/s13287-021-02160-9 – volume: 12 start-page: 479 year: 2021 ident: 2200_CR45 publication-title: Cell Death Dis doi: 10.1038/s41419-021-03763-z – ident: 2200_CR47 doi: 10.3892/or.2021.8114 – volume: 22 start-page: 1288 year: 2020 ident: 2200_CR8 publication-title: Nat Cell Biol doi: 10.1038/s41556-020-00580-y – volume: 21 start-page: 297 year: 2012 ident: 2200_CR16 publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.02.014 – volume: 71 start-page: 209 year: 2021 ident: 2200_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 10 start-page: 885 year: 2019 ident: 2200_CR48 publication-title: Cell Death Dis doi: 10.1038/s41419-019-2127-7 – volume: 62 start-page: 335 year: 2016 ident: 2200_CR46 publication-title: Mol Cell doi: 10.1016/j.molcel.2016.03.021 – volume: 19 start-page: 4101 year: 2021 ident: 2200_CR27 publication-title: Comput Struct Biotechnol J doi: 10.1016/j.csbj.2021.07.014 – volume: 11 start-page: 480 year: 2021 ident: 2200_CR35 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-0331 – volume: 9 start-page: 347 year: 2018 ident: 2200_CR51 publication-title: Cell Death Dis doi: 10.1038/s41419-018-0376-5 – volume: 38 start-page: 101801 year: 2021 ident: 2200_CR24 publication-title: Redox Biol doi: 10.1016/j.redox.2020.101801 – volume: 7 start-page: 61 year: 2019 ident: 2200_CR28 publication-title: Front Cell Dev Biol doi: 10.3389/fcell.2019.00061 – volume: 19 start-page: 40 year: 2020 ident: 2200_CR44 publication-title: Mol Cancer doi: 10.1186/s12943-020-01161-1 – volume: 10 start-page: 4056 year: 2020 ident: 2200_CR52 publication-title: Theranostics doi: 10.7150/thno.40860 – volume: 563 start-page: 249 year: 2018 ident: 2200_CR61 publication-title: Nature doi: 10.1038/s41586-018-0666-1 |
| SSID | ssj0061919 |
| Score | 2.5468123 |
| Snippet | Background Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD... Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from... Abstract Background Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies... |
| SourceID | doaj pubmedcentral proquest gale crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 1 |
| SubjectTerms | Adenocarcinoma ALKBH5 Analysis Animal experimentation Cloning Development and progression Efficiency Enzyme-linked immunosorbent assay Experiments Glucose Glucose metabolism Health aspects Lung cancer Methylation Methyltransferases METTL3 Plasmids Prognosis Protein binding Proteins RNA RNA-protein interaction translation Tumorigenesis Tumors YTHDF1 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3JatwwVJQcSi-lK3WbpCoUeigilmwtPk5CQihkCqWB3IRGSxsY2yHjOZT-fN7zMsQptJeeDNYTtt7-0FsI-ZhiArMKnpvB0QHlSkhmguQsgblPyoHFTFg7fLFU55fllyt5dW_UF-aEDe2BB8QdBSN8EB4UrUolT74CBsqLwimd6ySLvo4cbN4UTA06GKICXk0lMkYdbTheADJMR8DK0pzJmRnqu_X_qZMf5kneMzxnz8jT0WOki-FPn5NHsXlBHl-Md-IvyW-gNMUO4A0I65piuuCGtonWakG_LRe0bgOmA_UUoF1LQaZrnNkV6enyK2fTFNyO_lj_Aq7ADiXUNYF22xqnZqEuhDfXDV2DXqAOQMH83cK329q9Ipdnp99Pztk4UoF5mfOOcQ7PKrkolMRsGFFBBOxVAuSC3TeuzINPOkVYBMcIcM-9UoaXqyCcAboVr8le0zbxDaFayKBdwVMlQimcc6uocq-9Et4HCBszwicMWz_2G8exF2vbxx1G2YEqFqhie6pYmZHPuz03Q7eNv0IfI-F2kNgpu38B_GNH_rH_4p-MvEey26HsdCfvdqEqLHLQusrIpx4CJR4O4N1YuABowN5ZM8j9GSRIqp8vT6xlR02xsULhxWcBblRGPuyWcSdmvzWx3SIMDl1H1ZoRPWPJ2dnnK831z75buNGgonX19n8g6x15IrD8I-dMyH2y191u4wE4Zd3qsJe_O01PMYI priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifmK9UyMIPki4Jm2S9klWueMQbgXxYN9CNmnOg2177nYf5P55Z7LpahXuqdBMKclkfjOTzAch70ITQK2C5VZh64ByKSSrvOQsgLoPyoLGDJg7fD5XZxfll4VcpAO3TQqrHDExArXvHZ6RHwuFF0QFqJuP1z8Zdo3C29XUQuMuuYelyzCkSy_2Dhf4BrGxB2hIxdCuH5NmKnW84XglyDBAAXNNcyYniinW7_8fpf-NnPxLFZ0-Ig-TDUlnO6Y_Jnea7gm5f55uyZ-SG-A9xZrgHYjvimIA4Yb2gbZqRr_NZ7TtPQYIRZ7Qoacg5S128WroyfwrZ2Nf3IFern7BPsGaJdR2ng7bFlcE0RHeXHV0BUhBLZCCQlzDv_vWPiMXpyffP5-x1GSBOZnzgXEOzzrYRiiJ8TGiBp_YqaBUAEugsmXuXdChgUEwlXwluFOq4uXSC1sBJ4vn5KDru-YFoVpIr23BQy18Kay1y0blTjslnPPgSGaEjytsXKpAjo0wViZ6IpUyO64Y4IqJXDEyIx_231zv6m_cSv0JGbenxNrZ8UW_vjRJFA3MwXnhQHWrUPLgaoCkvCis0rkOstAZeYNsN7tE1D0CmJmqMe1B6zoj7yMFYgBMwNmUygDLgNW0JpRHE0qQXTcdHreWSdixMX92ekbe7ofxS4yH65p-izTYhh3BNiN6siUnc5-OdFc_Yv3wSgNo6_rl7T8_JA8EpnrknAl5RA6G9bZ5BQbYsHwdpew3Q-Ir2A priority: 102 providerName: ProQuest |
| Title | The essential roles of m6A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma |
| URI | https://www.proquest.com/docview/2630473152 https://www.proquest.com/docview/2622957870 https://pubmed.ncbi.nlm.nih.gov/PMC8788079 https://doaj.org/article/d82cd2c0366f41fc9794033a6707f537 |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9NAEB_uA8QX8ROjZ11B8EGi2U2ymzyItNLjEFqlWDh8Wbab7N1Bm2ibgof_vDPbpBg97qWF7KTtZr67M_MDeO1Kh24VI7eMoAOShUjDrEh56NDdO2nQYzrqHZ5M5dk8-Xyenh9AB3fUPsDNjakd4UnN18t3v35ef0SF_-AVPpPvN5yO90IqNqC-0ShMD-EYPZMiRZ0k-1MFzBU80EeEMUGISWHWNdHc-Bk9R-Xn-f9vtf-tpPzLNZ3eh3ttTMmGOyF4AAdl9RDuTNpT80fwG2WB0YzwCtV5yaigcMNqx1ZyyGbTIVvVBRUMeR6xpmao9StC9SrZePqFhx1ObsMultcoNzTDhJmqYM12RbhaZC3xylXFlmg5mEFSdJBr_O56ZR7D_HT87dNZ2IIuhDaNeBNyju-5M6WQKdXLiBxzZCudlA4jg8wkUWGdciUuYuhUZIJbKTOeLAphMuRs_ASOqroqnwJTIi2UibnLRZEIY8yilJFVVgprC0wsA-DdE9a2nUhOwBhL7TOTTOodVzRyRXuu6DSAt_t7fuzmcdxKPSLG7Slplra_UK8vdKuaGvdgC2HRlUuXcGdzNFFRHBupIuXSWAXwktiud42pe4ughzKnNgil8gDeeAqSUtyANW1rAz4Gmq7VozzpUaIu2_5yJ1q6UwUtJB2NxhhoBfBqv0x3Un1cVdZboiFYdjK-AaieSPb23l-pri79PPFMoRFX-bPbf9tzuCuo9SPioUhP4KhZb8sXGJA1iwEcqnM1gOPRePp1NvB_awy85uHrbPT9D2_bMzw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviE8RGMxIIB6QtdhJ7OQBoQ46dWwtaNqkvXmuHY9JbTLaVGjif-Jv5C5NCgFpb3uqFF-aOnf-_Xz1fRDy2uceaBV2bim2DognImGpSzjzQPdeGmBMj7nDo7EcnsSfT5PTDfKrzYXBsMoWE2ugdqXF_8h3hMQDogjo5sPld4Zdo_B0tW2hsTKLg_zqB7hsi_f7n0C_b4TYGxx_HLKmqwCzScgrxjl8Zt7kQiYYECIycAKt9FJ6oL7UxKGzXvkcBmFv4FLBrZQpjydOmBR-egTfe4tsxhHc2yObu4Px16MW-8EbqVuJACdLhp5Em6aTyp0Fx0NIhiERmN0asqRDhXXHgP954d9Yzb_Ib-8-udfsWml_ZWYPyEZePCS3R825_CPyE6yNYhXyAgBjSjFkcUFLT2eyT4_GfTorHYYk1VZAq5ICrsywb1hOB-MvnLWdeCt6Pr0Cy8QqKdQUjlbLGeoA8RiuXBR0CthEDYgCBc_h2eXMPCYnN6KAJ6RXlEX-lFAlEqdMxH0mXCyMMZNchlZZKax14LoGhLdvWNum5jm23pjq2vdJpV5pRYNWdK0VnQTk3fqey1XFj2uld1Fxa0ms1l1fKOfnuln8GuZgnbCwWZA-5t5mAIJhFBmpQuWTSAVkG9WuV6mva8zRfZlhooVSWUDe1hKIOjABa5rkCXgNWL-rI7nVkQS0sN3h1rR0g1YL_WdtBeTVehjvxAi8Ii-XKION3xHeA6I6JtmZe3ekuPhWVyxPFdCEyp5d__Btcmd4PDrUh_vjg-fkrsBEk5AzkWyRXjVf5i9g-1dNXjZrjpKzm17mvwGzxWgr |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+essential+roles+of+m6A+RNA+modification+to+stimulate+ENO1-dependent+glycolysis+and+tumorigenesis+in+lung+adenocarcinoma&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Ma%2C+Lifang&rft.au=Xue%2C+Xiangfei&rft.au=Zhang%2C+Xiao&rft.au=Yu%2C+Keke&rft.date=2022-01-25&rft.pub=BioMed+Central+Ltd&rft.issn=0392-9078&rft.volume=41&rft.issue=1&rft_id=info:doi/10.1186%2Fs13046-021-02200-5&rft.externalDocID=A693514779 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |